Zobrazeno 1 - 10
of 825
pro vyhledávání: '"first-pass metabolism"'
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Background The present research work aims to develop a Ropinirole-loaded self-Nanoemulsifying Drug Delivery system. Ropinirole has limited oral bioavailability due to substantial first-pass metabolism, which ultimately results in poor oral b
Externí odkaz:
https://doaj.org/article/289d6e9434444cb4b4623f227c684891
Autor:
Natalia V. Bakulina, Sergey V. Tikhonov, Sergey V. Okovityi, Elena A. Lutaenko, Alexandеr O. Bolshakov, Veronika A. Prikhodko, Anna S. Nekrasova
Publikováno v:
Терапевтический архив, Vol 94, Iss 12, Pp 1431-1437 (2023)
The MedLine database contains 570 publications, including 71 randomized clinical trials and 6 meta-analyses on the rebamipide molecule in 2022. Indications for the use of rebamipide are gastric ulcer, chronic gastritis with hyperacidityin the acute s
Externí odkaz:
https://doaj.org/article/854065ccdd4f4d0788bc00d7afd90d2c
Publikováno v:
Current Issues in Molecular Biology, Vol 43, Iss 3, Pp 1592-1605 (2021)
Collagen hydrolysates (CHs) are composed of bioactive peptides (BAPs), which possess health enhancing properties. There is a knowledge gap regarding the bioavailability of these BAPs that involves intestinal transport and hepatic first pass effects.
Externí odkaz:
https://doaj.org/article/3912ccc1752f4f39b882bde1a578fb8e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tim Quach, Luojuan Hu, Sifei Han, Shea F. Lim, Danielle Senyschyn, Preeti Yadav, Natalie L. Trevaskis, Jamie S. Simpson, Christopher J. H. Porter
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/028048587b0e4741b75102697e74ef15
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Vol 58 (2022)
Abstract Hydralazine hydrochloride is an anti-hypertensive drug. The drug has poor oral bioavailability (BA) of about 30- 50% due to extensive first-pass metabolism. Hence, the buccal delivery was used to enhance the BA of hydralazine hydrochloride.
Externí odkaz:
https://doaj.org/article/a60c62a680fd4c61848837cb6721622b
Autor:
Tim Quach, Luojuan Hu, Sifei Han, Shea F. Lim, Danielle Senyschyn, Preeti Yadav, Natalie L. Trevaskis, Jamie S. Simpson, Christopher J. H. Porter
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Buprenorphine (BUP) is a potent opioid analgesic that is widely used for severe pain management and opioid replacement therapy. The oral bioavailability of BUP, however, is significantly limited by first-pass metabolism. Previous studies have shown t
Externí odkaz:
https://doaj.org/article/075b84dedb714267a4a31fc5ae8108b9
Publikováno v:
International Journal of Nanomedicine, Vol Volume 15, Pp 6503-6518 (2020)
Jing-Yi Ye,1 Zhong-Yun Chen,1 Chuan-Li Huang,1 Bei Huang,2 Yu-Rong Zheng,2 Ying-Feng Zhang,1 Ban-Yi Lu,2 Lin He,2 Chang-Shun Liu3 ,* Xiao-Ying Long1,4, * 1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, People’s Republic
Externí odkaz:
https://doaj.org/article/360c833b9d1b495e93184a14733fc7dd
Publikováno v:
Pharmaceutics, Vol 14, Iss 12, p 2743 (2022)
Ezetimibe (EZE) is a selective cholesterol absorption inhibitor. Hepatic impairment significantly increases the systemic exposure of EZE and its main active phenolic glucuronide, EZE-Ph. Although changes in efflux transporter activity partly explain
Externí odkaz:
https://doaj.org/article/1d425ec9df5949639c0c2fe38cb59bbb
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/0e07b10331604beb8490ae975512f8b9